2024 Recognized Abstracts | American Diabetes Association (2024)

We are excited to highlight a select group of abstracts that have been chosenfor recognition at the 84th Scientific Sessions in Orlando. You can find these abstracts in the Scientific Sessions Meeting App.

ADA Presidents’ Select Abstracts

The following abstracts were identified as noteworthy by the Scientific Sessions Meeting Planning Committee Chair and are being presented at the 84th Scientific Sessions as oral presentations:

9-OR: Targeting Inflammation with Salsalate in Type 1 Diabetes Neuropathy (TINSAL-T1DN Trial)

LYNN ANG, YIYUAN HUANG, CATHERINE MARTIN, KARA R. MIZOKAMI-STOUT, YU KUEI LIN, ALEXI VASBINDER, MOUSUMI BANERJEE, SALIM HAYEK, EVA L. FELDMAN, RODICA BUSUI, Ann Arbor, MI

17-OR: Oral Bisphenol A Administration Decreased Peripheral Insulin Sensitivity in Healthy Adults

ADAM SEAL, STEVEN K. MALIN, ANDREW SCHAFFNER, MICHAEL R. HUBBARD, SARAH K. KEADLE, HANNAH BRUNNER-GAYDOS, ALIA A. ORTIZ, JANE E. NAKAMURA, CLARA MCMAHON, RACHEL BARNETT, ANITA H. KELLEHER, KELLY A. BENNION, SUZANNE PHELAN, TODD HAGOBIAN, San Luis Obispo, CA, New Brunswick, NJ, Gilbert, AZ, San, CA, Seattle, WA, San Francisco, CA

74-OR: CGM Metrics from Five Studies Identify Participants at High Risk of Imminent Type 1 Diabetes (T1D) Development

PETER CALHOUN, CHARLEY SPANBAUER, ANDREA STECK, BRIGITTE I. FROHNERT, MARK A. HERMAN, BART KEYMEULEN, SR., RIITTA VEIJOLA, JORMA TOPPARI, ASTER DESOUTER, FRANS K. GORUS, MARK A. ATKINSON, DARRELL M. WILSON, SUSAN PIETROPAOLO, ROY BECK, Tampa, FL, Aurora, CO, Oulu, Finland, Turku, Finland, Brussels, Belgium, Gainesville, FL, Stanford, CA, Houston, TX

122-OR: Lower Plasma Levels of Truncated Apolipoprotein C-I Are Associated with Increased Risk of Diabetes—Multiethnic Study of Atherosclerosis

JURAJ KOSKA, YUEMING HU, DEAN BILLHEIMER, DOBRIN NEDELKOV, MATTHEW BUDOFF, ALAIN BERTONI, ROBYN MCCLELLAND, PETER REAVEN, Phoenix, AZ, Tucson, AZ, Sugar Land, TX, Los Angeles, CA, Winston-Salem, NC, Seattle, WA

210-OR: Discovering Stimulatory State-Specific Type 2 Diabetes GWAS Mechanisms with Single-Cell Multiomics on iPSC-Derived Fibro-adipogenic Progenitor Cell Villages

CHRISTA VENTRESCA, ARUSHI VARSHNEY, PETER ORCHARD, YAO-CHANG TSAN, ANDRE MONTEIRO DA ROCHA, MARKKU LAAKSO, SR., JAAKKO TUOMILEHTO, TIMO A. LAKKA, KAREN L. MOHLKE, MICHAEL BOEHNKE, LAURA SCOTT, HEIKKI A. KOISTINEN, FRANCIS S. COLLINS, TODD J. HERRON, STEPHANIE BIELAS, STEPHEN PARKER, Kuopio, Finland, Chapel Hill, NC, Helsinki, Finland, Bethesda, MD, Ann Arbor, MI

257-OR: The Effect of a Reduced-Energy Diet upon Maternal Weight and Pregnancy Outcomes in Women with Gestational Diabetes—The DiGest Trial

LAURA C. KUSINSKI, DANIELLE JONES, NOORIA ATTA, ELIZABETH TURNER, LINDA M. OUDE GRIEP, KIRSTEN L. RENNIE, EMANUELLA DE LUCIA ROLFE, STEPHEN SHARP, HELEN R. MURPHY, ROY TAYLOR, CLAIRE L. MEEK, Cambridge, United Kingdom, Norwich, United Kingdom, Newcastle upon Tyne, United Kingdom

261-OR: Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity

ALICE L. FITZPATRICK, SUYA WANG, REBECCA REESE, NICOLE PICARD, EMILY COZZI, TIMOTHY J. KIEFFER, JAY CAPLAN, HARITH RAJAGOPALAN, Lexington, MA

337-OR: The LonP1 Protease Maintains Pancreatic ß-Cell Survival by Governing Mitochondrial Protein Folding

JIN LI, JIE ZHU, EMMA C. RECK, EMILY M. WALKER, SCOTT SOLEIMANPOUR, Ann Arbor, MI

Health Disparities Committee—Top 10 Recommended Abstracts

The “Health Disparities Committee’s Top 10 Recommended Abstracts” recognize health disparities related abstracts that have been accepted into the 84th Scientific Sessions of the American Diabetes Association®. These abstracts focus on health care disparities in diabetes outcomes, showcase research that explores the underlying factors in diabetes disparities, and demonstrate practical interventions that may contribute to eliminating those disparities.

652-P: Impact of a Six-Month Digital Health Coaching Program on Individuals with Type 2 Diabetes Mellitus Experiencing Food Insecurity in Rural Areas

JASMINE MOORE, SARAH RUTLAND, JANE MURPHY, MERCEDES TARASOVICH, Birmingham, AL.

544-P: Early Evidence from a Pragmatic Trial to Increase Uptake of Diabetes Self-Management Education and Support Services in Rural Health Care Systems in Kentucky

MARY E. LACY, JAMES KECK, JESSICA ELLIOTT, LAURA WRIGHT, VANCE H. DRAKEFORD, BRENT MCKUNE, AARON J. KRUSE-DIEHR, KEY DOUTHITT, Anchorage, AK, Lexington, KY, Jackson, KY.

1175-P: Mental Health and Glycemic Control Disparities among Latinx Adolescents with Type 1 Diabetes

ELIZABETH VARGAS, BAILEY TANNER, LAUREN B. SHOMAKER, HOLLY K. O'DONNELL, Aurora, CO, Fort Collins, CO.

1937-P: Coordinated Approach to Improve Quality of Care and Address Disparities in Patients with Cardiometabolic Disease—Analysis from the Cardiometabolic Center Alliance Registry

MIKHAIL N. KOSIBOROD, MELISSA L. MAGWIRE, EVAN L. O'KEEFE, DANIEL S. AISTROPE, EMILY ANDAYA, ANTHONY BASHALL, JAVED BUTLER, KATIE CUMMINGS, LISA DAVIS, ROBERT H. ECKEL, JONATHAN A. FIALKOW, LACY HARNESS, KEITH A. MILLER, IAN NEELAND, SHACHI PATEL, JORGE PLUTZKY, ROSALIE K. SAALFELD, ANDREA STAFOS, SANJAY RAJAGOPALAN, Kansas City, KS, Mission Hills, KS, Shelbyville, IN, Indianapolis, IN, Dallas, TX, Kansas City, MO, Miami, FL, Aurora, CO, Coral Gables, FL, Cleveland, OH, Boston, MA, Lincoln, NE, Baltimore, MD.

1930-LB: A Randomized Trial of Real-Time Continuous Glucose Monitoring (RT-CGM) with Culturally Tailored Education for Latino Patients with Type 2 Diabetes (DM)

NICOLE M. EHRHARDT, LORENA WRIGHT, LAURA MONTOUR, PETER BERBERIAN, EVELIN JONES, DARINKA D. GIL MENCHACA, ANA GABRIELA VASCONCELOS, BRYAN A. COMSTOCK, Burien, WA, Seattle, WA.

14-OR: Autonomous Artificial Intelligence Diabetic Eye Exams Mitigates Disparities in Screening Completion for Youth

DHRUVA PATEL, LEE A. BROMBERGER, NEHA PARIMI, ELIZABETH A. BROWN, ALVIN LIU, HAROLD LEHMANN, MICHAEL D. ABRÀMOFF, RISA M. WOLF, Baltimore, MD, Iowa City, IA.

208-OR: Impact of Carbohydrate-Restricted Nutrition Therapy and Continuous Remote Care among People with Type 2 Diabetes in Rural vs. Urban Areas

SHAMINIE J. ATHINARAYANAN, REBECCA N. ADAMS, CAROLINE G.P. ROBERTS, BRITTANIE M. VOLK, ALISON ZOLLER, AMY L. MCKENZIE, West Lafayette, IN, San Francisco, CA, Denver, CO.

1822-LB: Family Support for Diabetes Action (FAM-ACT) vs. Traditional Diabetes Management Education and Support—Randomized Comparative Effectiveness Trial

ANN-MARIE ROSLAND, GRETCHEN PIATT, EDITH C. KIEFFER, FELIX VALBUENA, GLORIA PALMISANO, DENISE J. DEVERTS, STEPHANIE PEREZ, JONATHAN YABES, CHRISTINA M. LALAMA, MICHELE HEISLER, Pittsburgh, PA, Ann Arbor, MI, Detroit, MI.

188-OR: Association of Social Determinants of Health with Efficacy of Metabolic Bariatric Surgery (MBS) vs. Medical Therapy (MT) for Type 2 Diabetes

MARY-ELIZABETH PATTI, BO HU, HANNA WANG, YAEL SARIG, DONALD C. SIMONSON, KATHY FOSTER, DANIELLE WOLFS, DAVID ARTERBURN, MATTHEW J. O'BRIEN, ASHLEY H. VERNON, JOHN M. JAKICIC, SANGEETA R. KASHYAP, ALI AMINIAN, PHILIP SCHAUER, DAVID E. CUMMINGS, WILLIAM F. GOURASH, ANITA COURCOULAS, JOHN P. KIRWAN, Cleveland, OH, Providence, RI, Seattle, WA, Chicago, IL, Boston, MA, Kansas City, KS, NY, NY, Baton Rouge, LA, Pittsburgh, PA.

1344-P: Socioeconomic Status Patterns in Remote Diabetic Retinopathy Screening Using Teleophthalmology

MARIA JESSICA CRUZ, TANVI CHOKSHI, LINDSEY NGUYEN, TREYSI G. VARGAS-RAMOS, ABRAHAM HANG, BLAKE M. SNYDER, GLENN YIU, Boston, MA, Sacramento, C.

ADA Interest Group Abstract Awards

Behavioral Medicine & Psychology

654- P: Insights on Inclusion—Tailoring a Health Insurance Toolkit to Diverse Emerging Adults with Type 1 Diabetes

CHANTEL S. SHANNON, ANUHYA K. KANCHIBHATLA, MARY JANE ROCHE, JORDEN RIEKE, CLAUDIA LEWIS, DIONNE A. WILLIAMS, ERIKA L. LUNDGRIN, BETUL HATIPOGLU, MICHELLE L. LITCHMAN, NANCY A. ALLEN,JULIA E. BLANCHETTE,Cleveland, OH,Boston, MA,Beachwood, OH,Salt Lake City, UT

Clinical Centers & Programs

746-P: GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes

FAIDAT A. ISHOLA, C. WILLIAM PIKE, SUN H. KIM,Stanford, CA,New York, NY

Diabetes & Cardiovascular Disease

245-OR: Proteomic Analysis of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA)—Results and Integrated Predictors of Response

ARMANDO VERGARA-MARTEL, JEAN-EUDES DAZARD, MIRELA DOBRE, KIM A. CONNELLY, JONNELLE EDWARDS-GLENN, GABRIEL TENSOL, CHERYL CAMERON, MARK CAMERON, SADEER G. AL-KINDI, ROBERT D. BROOK, MATTHEW R. WEIR, SANJAY RAJAGOPALAN,Cleveland, OH,Toronto, ON, Canada,Detroit, MI,Baltimore, MD

Diabetes In Primary Care

644-P: Racial Ethnic Disparities in Prescription of GLP1 Receptor Agonists for People at High Risk for Diabetes on Atypical Antipsychotics

JITHIN SAM VARGHESE, DAVID GOLDSMITH, RACHEL WAFORD, ROSETTE CHAKKALAKAL, MOHAMMED K. ALI, FRANCISCO J. PASQUEL, ROBERT O. COTES,Atlanta, GA

Diabetes In Youth

147-OR: Obesity Is Associated with Increased Clearance and Reduced Drug Exposure to Metformin in Youth with Type 2 Diabetes

SHYLAJA SRINIVASAN, KEVIN YEN, ALEXANDER FLOREN, RADA SAVIC,San Francisco, CA

Diabetes Self-Management Education & Support

579-P: ADA Diabetes Medical Management Plan Implementation—Barriers and Opportunities

CHRISTINE MARCH, JACQUELINE MCMANEMIN, MARGARET PELLIZZARI, JANET RODRIGUEZ, HENRY RODRIGUEZ, KAREN HARRIMAN, CRYSTAL WOODWARD,Pittsburgh, PA,Fairfax, VA,Lake Success, NY,Tampa, FL,Tamp, FL,Dunn Loring, VA,Arlington, VA

Diabetes Technology

37-OR: Effectiveness of Continuous Glucose Monitoring on Short-Term In-hospital Mortality among Frail Critically Ill Patients with COVID-19—An Exploratory, Prospective, Randomized, Open-Label, Parallel, Single-Center, Randomized Clinical Trial

WEI WANG,YUN SHEN,Shanghai, China,Baton Rouge, LA

Exercise Physiology

28-OR: Posttranslational Modifications in Skeletal Muscle Direct Divergent Metabolic Responses to Different Exercise Training Modes

MARK W. PATAKY, CARRIE J. HEPPELMANN, KYLE SEVITS, ANEESH K. ASOKAN, KATHERINE KLAUS, K. SREEKUMARAN NAIR,Rochester, MN

Eye Health

322-OR: Delaying Progression of Diabetic Retinopathy Worsen the Risk for Age-Related Macular Degeneration

WARD FICKWEILER, TANVI CHOKSHI, EMER O'DOHERTY, SURYA VISHVA TEJA JANGOLLA, NOLAN A. ZIEMNIAK, I-HSIEN WU, CRIS MARTIN JACOBA, SAMET GULKAS, ASSEL TALASPAYEVA, JERRY D. CAVALLERANO, LLOYD P. AIELLO, JENNIFER K. SUN, GEORGE L. KING,Chestnut Hill, MA,Boston, MA

Foot Care

172-OR: Lineage Tracing of Vasculogenic Fibroblasts In Vivo and Their Significance in the Rescue of Diabetic Ischemic Tissue

KANHAIYA SINGH, SUMIT S. VERMA, SASHWATI ROY, CHANDAN K. SEN, MANISHEKHAR KUMAR,Pittsburgh, PA

Health Care Delivery & Quality Improvement

1036-P: Cost-Effectiveness of Real-Time CGM vs. Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Intensive Insulin Therapy in Australia

HAMZA ALSHANNAQ, MOIN AHMED, GREGORY J. NORMAN, DAVID SIMMONS,San Diego, CA,Sydney, Australia,Campbelltown NSW, Australia

Immunology, Immunogenetics, & Transplantation

335-OR: Preliminary Results of Islet Survival in a Novel Biovascular Pancreas Implanted in Primates

MEHMET H. KURAL, KEVIN M. NASH, KALEB M. NAEGELI, HONG QIAN, JUAN WANG, ROBERT D. KIRKTON, LAURA E. NIKLASON,DURHAM, NC

Islet Biology, Development, & Function

103-OR: Signaling Mechanisms Underlying Islet Compensation in a Novel Mouse Model of ß-Cell Replication Deficiency

HANNAH R. FOSTER, SOPHIA SDAO, MELISSA ADAMS, BARAK BLUM, MATTHEW J. MERRINS,Madison, WI

Nutritional Science & Metabolism

17-OR: ADA Presidents' Select Abstract: Oral Bisphenol A Administration Decreased Peripheral Insulin Sensitivity in Healthy Adults

ADAM SEAL, STEVEN K. MALIN, ANDREW SCHAFFNER, MICHAEL R. HUBBARD, SARAH K. KEADLE, HANNAH BRUNNER-GAYDOS, ALIA A. ORTIZ, JANE E. NAKAMURA, CLARA MCMAHON, RACHEL BARNETT, ANITA H. KELLEHER, KELLY A. BENNION, SUZANNE PHELAN,TODD HAGOBIAN,San Luis Obispo, CA,New Brunswick, NJ,Gilbert, AZ,San, CA,Seattle, WA,San Francisco, CA

Pregnancy & Reproductive Health

1217-P: Insulin Sensitivity and Insulin Secretion Differentially Affect Birthweight and Postpartum Glucose

EMILY A. ROSENBERG, KAITLYN JAMES, DEEPTI PANT, SARAH HSU, ROBIN L. AZEVEDO, CHLOE MICHALOPOULOS, TANAYOTT THAWEETHAI, CAMILLE E. POWE, ARANTXA MEDINA BAEZ,Charleston, SC,Boston, MA,Bridgewater, MA

Public Health & Epidemiology

152-OR: Sex Differences in Metabolomics and Risk of Coronary Heart Disease in Type 2 Diabetes

YILIN YOSHIDA, DANTING LI, XIANG LI, VIVIAN FONSECA, FRANCK MAUVAIS-JARVIS, LU QI,New Orleans, LA

WIN ADA Abstract Awards

Basic Science: Islet Biology, Immunology, Physiology, or Obesity

112-OR: A Novel Function of Endothelial Insulin-Like Growth Factor-1 Receptor—Regulation of Gastrointestinal Microbiota as a Defensive Mechanism against Obesity-Induced Metabolic Dysfunction

NATALIE J. HAYWOOD, CHEUKYAU LUK, TIMOTHY S. FUTERS, MELANIE REAY, NATALLIA MAKAVA, ANNA SKROMNA, RICHARD CUBBON, MARK KEARNEY,Leeds, United Kingdom

Behavioral Medicine, Nutrition, Exercise, and Education

611-P: Effect of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) during a Nutrition Intervention on Time in Range (TIR)

HOLLY J. WILLIS, STEPHEN E. ASCHE, AMY L. MCKENZIE, REBECCA N. ADAMS, SHANNON KRIZKA, CAROLINE G.P. ROBERTS, BRITTANIE M. VOLK, SHAMINIE J. ATHINARAYANAN, ALISON R. ZOLLER, RICHARD M. BERGENSTAL,Minneapolis, MN,Bloomington, MN,Denver, CO,San Francisco, CA

Clinical Diabetes, Epidemiology, and Diabetes Complications

1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58

YU MI KANG, GIORGIO E.M. MELLONI, AVIVIT CAHN, ITAMAR RAZ, FILIPE MOURA, DEEPAK L. BHATT, SILVIO E. INZUCCHI, LAWRENCE A. LEITER, DARREN K. MCGUIRE, JOHN WILDING, INGRID A. GAUSE-NILSSON, JAN OSCARSSON, NICHOLAS MARSTON, CHRISTIAN T. RUFF, MARC S. SABATINE, STEPHEN D. WIVIOTT,Jerusalem, Israel,Boston, MA,New Haven, CT,Toronto, ON, Canada,Dallas, TX,Liverpool, United Kingdom,Mölndal, Sweden

Sex as a Biological Variable

1437-P: Blood Pressure (BP) Trajectories and 32-Year Cardiovascular Disease (CVD) Incidence in Women and Men with Type 1 Diabetes (T1D)

RACHEL G. MILLER, TREVOR J. ORCHARD, TINA COSTACOU,Pittsburgh, PA

2024 Recognized Abstracts | American Diabetes Association (2024)

FAQs

What is the ADA 2024 update for diabetes? ›

In the 2024 update, the ADA focused on patient-centered care, person-first language, and updated screening and treatment approaches based on the latest clinical evidence. In diabetes health care maintenance, the ADA emphasizes patients' individual preferences and goals, care costs, and treatment burdens.

What is the diabetes article 2024? ›

The 2024 Standards of Care includes revisions to incorporate person-first and inclusive language. Efforts were made to consistently apply terminology that empowers people with diabetes and recognizes the individual at the center of diabetes care.

What are the new A1c guidelines? ›

An A1c goal of less than 7% is appropriate, and more stringent A1c goals of less than 6.5% could be reasonable for individuals if they can be achieved without significant hypoglycemia or negatively impacts on well-being.

What are the highlights of the ADA 2024? ›

What's New in the 2024 ADA Standards of Care?
  • person-centered care.
  • obesity measurements.
  • weight-loss medications.
  • evaluation and management of comorbidities.
  • diabetes diagnosis and classification.
  • patient self-management and education.
Feb 14, 2024

What is the A1C goal for ADA 2024? ›

The recommendations include blood glucose levels that appear to correlate with an A1C of <7% (<53 mmol/mol).

What is the normal range for blood sugar in the American Diabetes Association? ›

Fasting Plasma Glucose (FPG)
ResultFasting Plasma Glucose (FPG)
Normalless than 100 mg/dL
Prediabetes100 mg/dl to 125 mg/dL
Diabetes126 mg/dL or higher

What A1C is no longer diabetic? ›

Because reversal can imply a permanent cure, a more apt term for this topic might be “diabetes remission.” This generally means reducing A1C to the level of someone without diabetes (less than 6.5%) and either eliminating diabetes medications altogether or limiting medication to metformin.

What is the target A1C for seniors? ›

In cohort studies, it has been demonstrated that the best survival is present in elderly people with an A1C between 7.0% to 8.0%, and values above and below this range are associated with increased mortality (35,36).

What A1C is not considered diabetic? ›

A1C results

Normal: below 5.7% Prediabetes: 5.7% to 6.4% Diabetes: 6.5% or above.

Where is the ADA meeting in 2024? ›

iCare is attending the ADA annual meeting on June 21 – 24, 2024 at the Orange County Convention Center in Orlando, Florida.

What year is the latest ADA standards? ›

The 2010 Standards replace DOJ's original 1991 ADA Standards (see below) and are the most current ADA standards from the federal government. DOJ allowed immediate use of the 2010 Standards as an alternative to the original 1991 standards.

What is title III of the ADA? ›

Title III prohibits discrimination on the basis of disability in the activities of places of public accommodations (businesses that are generally open to the public and that fall into one of 12 categories listed in the ADA, such as restaurants, movie theaters, schools, day care facilities, recreation facilities, and ...

What are the new ADA guidelines for diabetes? ›

The latest ADA guidelines recommend that everyone with diabetes 6 months of age and older be up to date on COVID-19 vaccinations and boosters as well as the inactive or recombinant version of annual influenza vaccinations.

What are the new diabetes medications for 2024? ›

In January 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a multi-dose version of Mounjaro called Mounjaro Kwikpen to treat people with type 2 diabetes.

What is the diabetes conference for 2024? ›

The 2024 Annual Mid-Atlantic Diabetes and Obesity Research Symposium is co-organized by the Diabetes, Endocrinology, and Obesity Branch (DEOB) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH); the Perelman School of Medicine at the University of ...

What is the new limit for diabetes? ›

A fasting blood sugar level less than 100 mg/dL (5.6 mmol/L) is normal. A fasting blood sugar level from 100 to 125 mg/dL (5.6 to 6.9 mmol/L) is considered prediabetes. If it's 126 mg/dL (7 mmol/L) or higher on two separate tests, you have diabetes.

Top Articles
Latest Posts
Article information

Author: Prof. Nancy Dach

Last Updated:

Views: 5673

Rating: 4.7 / 5 (77 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Prof. Nancy Dach

Birthday: 1993-08-23

Address: 569 Waelchi Ports, South Blainebury, LA 11589

Phone: +9958996486049

Job: Sales Manager

Hobby: Web surfing, Scuba diving, Mountaineering, Writing, Sailing, Dance, Blacksmithing

Introduction: My name is Prof. Nancy Dach, I am a lively, joyous, courageous, lovely, tender, charming, open person who loves writing and wants to share my knowledge and understanding with you.